These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 11777502)

  • 1. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential.
    Crispens MA; Bodurka D; Deavers M; Lu K; Silva EG; Gershenson DM
    Obstet Gynecol; 2002 Jan; 99(1):3-10. PubMed ID: 11777502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases.
    Deavers MT; Gershenson DM; Tortolero-Luna G; Malpica A; Lu KH; Silva EG
    Am J Surg Pathol; 2002 Sep; 26(9):1129-41. PubMed ID: 12218569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.
    Matsuo K; Wong KK; Fotopoulou C; Blake EA; Robertson SE; Pejovic T; Frimer M; Pardeshi V; Hu W; Choi JS; Sun CC; Richmond AM; Marcus JZ; Hilliard MAM; Mostofizadeh S; Mhawech-Fauceglia P; Abdulfatah E; Post MD; Saglam O; Shahzad MMK; Karabakhtsian RG; Ali-Fehmi R; Gabra H; Roman LD; Sood AK; Gershenson DM
    J Surg Oncol; 2018 Feb; 117(2):236-244. PubMed ID: 28787528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
    Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
    Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian serous borderline tumors with invasive peritoneal implants.
    Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
    Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
    Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
    Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.
    Shvartsman HS; Sun CC; Bodurka DC; Mahajan V; Crispens M; Lu KH; Deavers MT; Malpica A; Silva EG; Gershenson DM
    Gynecol Oncol; 2007 Jun; 105(3):625-9. PubMed ID: 17320156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary surgery in patients with serous low malignant potential ovarian tumors with peritoneal implants.
    Kane A; Uzan C; Rey A; Gouy S; Duvillard P; Morice P
    Int J Gynecol Cancer; 2010 Apr; 20(3):346-52. PubMed ID: 20375795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
    Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
    Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
    Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
    Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
    Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
    Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
    Javellana M; Hoppenot C; Lengyel E
    Gynecol Oncol; 2019 Feb; 152(2):228-234. PubMed ID: 30471899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up.
    Longacre TA; McKenney JK; Tazelaar HD; Kempson RL; Hendrickson MR
    Am J Surg Pathol; 2005 Jun; 29(6):707-23. PubMed ID: 15897738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
    Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
    Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
    Jansaka N; Suprasert P
    Asian Pac J Cancer Prev; 2014; 15(24):10837-40. PubMed ID: 25605186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
    da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
    Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.